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Fusion peptideA panel of eight single amino acid deletion mutants was generated within the ﬁrst 24 residues of the fusion
peptide domain of the of the hemagglutinin (HA) of A/Aichi/2/68 inﬂuenza A virus (H3N2 subtype). The
mutant HAs were analyzed for folding, cell surface transport, cleavage activation, capacity to undergo acid-
induced conformational changes, and membrane fusion activity. We found that the mutant ΔF24, at the C-
terminal end of the fusion peptide, was expressed in a non-native conformation, whereas all other deletion
mutants were transported to the cell surface and could be cleaved into HA1 and HA2 to activate membrane
fusion potential. Furthermore, upon acidiﬁcation these cleaved HAs were able to undergo the characteristic
structural rearrangements that are required for fusion. Despite this, all mutants were inhibited for fusion
activity based on two separate assays. The results indicate that the mutant fusion peptide domains associate
with target membranes in a non-functional fashion, and suggest that structural features along the length of
the fusion peptide are likely to be relevant for optimal membrane fusion activity.
© 2009 Elsevier Inc. All rights reserved.Introduction
All enveloped viruses encode glycoproteins that function to
mediate fusion of their membranes with those of host cells during
the initial stages of infection. Such viral fusion proteins (VFPs) are
designed to respond to external stimuli at the appropriate time and
place, to rearrange their molecular structures and initiate the fusion
process. Membrane fusion can occur at the plasma membrane of host
cells, often following the engagement of receptor molecules, or within
subcellular compartments such as endosomes following internaliza-
tion and acidiﬁcation of the local environment (Harrison, 2008;
Kielian and Rey, 2006; Lamb and Jardetzky, 2007; Weissenhorn et al.,
2007; White et al., 2008). Often, more than one viral protein is
involved, and for some viruses multiple cellular components take part
in the fusion process. However, for most enveloped viruses a single
membrane anchored VFP serves as the principal protagonist for
drawing the membranes into proximity with one another to initiate
the fusion event. For these VFPs, the structural rearrangements that
trigger fusion are generally coincident with the exposure of relatively
hydrophobic domains to allow for their interaction with cellular
target membranes. These “fusion peptide” domains are known to
occur in one of three basic forms; (i) they can be present at the N-
terminus of the fusion subunit of the protein, (ii) they can resideA. Steinhauer).
ll rights reserved.within the polypeptide chain as single loop internal fusion peptide
domains, and (iii) they can exist as internal bipartite loops.
Most of the VFPs that have been characterized appear to share
some of the mechanistic features for bringing viral and cellular
membranes into proximitywith one another in the initial stages of the
fusion process. However, VFPs are often segregated into three classes,
based primarily on common structural considerations. Among these,
representatives of Class I VFPs from members of the orthomyxovir-
idae, paramyxoviridae, and retroviridae families have been particu-
larly well characterized. For these VFPs, polypeptide precursors
associate to form trimers that are cleaved to generate N-terminal
fusion peptides on their membrane-anchored subunit. During the
fusion process, these membrane-anchored subunits undergo con-
formational changes to generate highly stable helical rod structures.
As a consequence, the N-terminal fusion peptides are relocated to the
same end of the molecule as the C-proximal viral membrane anchor
domain. The molecular rearrangements and end-state structures for
Class I VFPs are consistent with a model for membrane fusion, in
which N-terminal fusion peptides are directed to interact with cellular
target membranes, and formation of helical rod structures bring the
viral and cellular membranes into proximity to one another as a
prelude to the fusion process.
The inﬂuenza A virus hemagglutinin glycoprotein (HA) serves as
the prototype for the Class I VFPs. It is synthesized as polypeptide
chains of approximately 550 amino acids that associate non-
covalently as homotrimers. The precursor form of the trimer (HA0)
322 W.A. Langley et al. / Virology 394 (2009) 321–330requires proteolytic cleavage of each monomer into the disulﬁde-
linked subunits HA1 and HA2 in order to activate membrane fusion
potential and virus infectivity (Appleyard and Maber, 1974; Klenk et
al., 1975; Lazarowitz and Choppin, 1975). Cleavage of HA0 not only
liberates the HA2 N-terminal fusion peptide domain, but allows the
HA to assume a neutral pH conformation that can subsequently be
triggered by acidiﬁcation to undergo the conformational changes
required for membrane fusion (Bizebard et al., 1995; Bullough et al.,
1994; Chen et al., 1999).
Although the fusion peptides of all Class I VFPs feature several
large hydrophobic amino acids and include a number of glycine
residues interspersed along their length, there is no direct sequence
homology outside of the individual virus families. By contrast, the HA
fusion peptide domains of all16 HA subtypes of inﬂuenza A viruses, as
well as those of inﬂuenza B viruses, are highly homologous. This is
particularly evident within the N-terminal 11 residues, and at
positions with large hydrophobic or glycine residues (Fig. 1A). The
reason for such conservation is likely due to constraints on the folding
of the precursor HA0 structure, the capacity of this structure to be
cleaved into a neutral pH structure that is responsive to acidiﬁcation,
and the requirement that fusion peptides be capable of adopting
functional structures while interacting with target membranes to
initiate the process of membrane fusion.
A number of studies on expressed proteins and mutant inﬂuenza
viruses have focused on the membrane fusion properties of mutant
HAs with changes in the fusion peptide domain (Cross et al., 2001;
Daniels et al., 1985; Gething et al., 1986; Korte et al., 2001; Lai and
Tamm, 2007; Lin et al., 1997; Nobusawa et al., 1995; Qiao et al., 1999;
Steinhauer et al., 1995; Yewdell et al., 1993). Among the implications
derived from these studies, the N-terminal glycine has been
demonstrated as particularly important for fusion activity, and large
hydrophobic residues at positions 2, 3, 6, 9, and 10 are desirable forFig. 1. A) HA Fusion peptide sequences from representatives of each of the 16 HA subtypes. H1
H5: A/Chick/Pennsylvania/1370/83, H6: A/Shearwater/Australia/1/72, H7: A/FPV/Rostoc
Germany/N/49, H11: A/Duck/England/56, H12: A/Duck/Alberta/60/76, H13: A/Gull/M
1983, H16: A/Black-Headed Gull/Sweden/2/99. B) Nomenclature and fusion peptide sequ
deletion of the amino acid residue at this position.optimal function. The conserved tryptophan at HA2 position 14 also
appears to play a fundamental role for fusion. The glycine at position 4
has been shown to tolerate changes in functional HAs, but the glycine
at position 8may bemore critical, and numerous observations suggest
that the spacing of glycine residues in fusion peptides may be
important for fusion peptides to adopt functional structures.
The actual length of fusion peptide domains has not been
addressed in great detail, particularly as components of intact HA
molecules. Experiments on mutants with a deletion of either the
N-terminal glycine or the leucine at HA2 position 2 were shown to be
non-functional, using assays with synthetic peptide analogs or full
length expressed HAs (Steinhauer et al., 1995; Wharton et al., 1988).
Further evidence for length constraints in the terminal region of the
inﬂuenza fusion peptide derive from studies on cleavage activation
mutants selected for growth in the presence of the protease
thermolysin (Orlich and Rott, 1994). This protease cleaves HA0
between the residues that normally constitute HA2 Gly1 and Leu2,
which generates an HA2 subunit with leucine at the N-terminus and a
fusion peptide that is truncated by one residue. However, mutants
selected for growth in the presence of thermolysin were found to
contain single residue insertions just downstream of the N-terminal
leucine, which functioned to restore authentic fusion peptide length.
For the present study, we extended previous analyses on the
length requirements for functional inﬂuenza HA fusion peptide
sequences using expressed HAs with single residue deletions that
span this domain. We found that with one exception, themutants fold
into native HAs that were expressed on cell surfaces, cleaved into HA1
and HA2, and were able to undergo the acid-induced conformational
changes requisite for fusion. However, all mutants were debilitated
for membrane fusion function, suggesting either an overall length
requirement for these fusion peptide sequences, a requirement for
particular structural elements along the length of this domain, or: A/PR/8/34, H2: A/Japan/305/57, H3: A/Aichi/2/68, H4: A/Duck/Czechoslovakia/56,
k/34, H8: A/Turkey/Ontario/6118/68, H9: A/Turkey/Wisconsin/66, H10: A/Chicken/
aryland/704/77, H14: A/Mallard/Astrakhan/263/1982, H15: A/Duck/Australia/341/
ences of the HA deletion mutants addressed in this study. The symbol Δ denotes the
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peptide sequences.Results and discussion
In previous studies, single residue deletion mutants of glycine at
the HA2 N-terminus and leucine at position 2 have been characterized
using fusion peptide analogs, expressed HAs, and laboratory-selected
mutants (Orlich and Rott, 1994; Steinhauer et al., 1995; Wharton et
al., 1988). The results of these studies suggest that single residue
deletions at Gly1 or Leu2 lead to inhibition of fusion activity. Here we
assess the structural properties andmembrane fusion activity of seven
additional single amino acid deletions along the length of the fusion
peptide using expressed HAs derived from the parental inﬂuenza
virus A/Aichi/2/68, an H3 subtype. The nomenclature and positions
of deletion mutants examined in this study are shown in Fig. 1B. Fig. 1
also includes the fusion peptide sequences of representatives of the 16
HA subtypes as a reference. The ΔL2 mutant has been characterized
previously, but was included in the current study as an additional
control. The previous study showed that ΔL2 HA to fold properly and
undergo conformational changes in response to acidic pH, but was
negative for fusion activity (Steinhauer et al., 1995).
Fig. 2 shows three conformations that the HA assumes during the
inﬂuenza life cycle, with fusion peptide residues highlighted in
yellow. In the HA0 precursor structure, the residues that constitute
the N-terminal portion of the fusion peptide form the membrane
proximal half of the surface loop that is recognized by activating
proteases (Chen et al., 1998). In the cleaved neutral pH HA, theseFig. 2. Ribbon diagrams of the three conformations of the HA trimer. The HA0 precursor s
cleavage are depicted in blue, and the HA2 subunits in red. In all three structures, the residue
In the left panel, the cleavage loop of one of the HA0monomers can be seen extending from t
the HA structure remains unchanged following cleavage, the major structural consequence b
cleavage loop to the interior of the trimer. The right panel shows the structure of the HA2 tri
In this thermostable rod-like structure, the fusion peptide and the viral transmembrane dom
both the fusion peptide and the 10-residue peptide that links it to HA2 residues of known st
sites remain unchanged following proteolytic activation into the neutral pH cleaved structu
shown in the right panel. The panel in the lower right corner depicts a magniﬁed view of the
that were deleted in this study are shown as yellow spheres. The positions of HA1 residueresidues are relocated into a cavity in the interior of the trimer, where
they make contacts with ionizable residues that are thought to be
signiﬁcant for priming the HA for subsequent conformational changes
in response to acidiﬁcation (Chen et al., 1998; Thoennes et al., 2008;
Wilson et al., 1981). In the low pH structure that results following the
conformational changes required for fusion, the fusion peptide is
relocated to the end of the helical rod structure to facilitate interaction
with the target membrane (Bullough et al., 1994; Chen et al., 1999).
Therefore, residues that constitute the fusion peptide provide critical
roles in the context of each of the major HA conformations. The
rationale behind the choice of HA2 positions for the current deletion
studies was to cover the length of the HA2 N-terminal region from the
N-terminus through the conserved aromatic residue (Y or F) at
position 24, as residue 25 is not conserved and is often a charged or
polar amino acid (Fig. 1). Individual positions for deletion were
selected on the basis of previous observations on natural isolates or
laboratory mutants, which showed that residues with alternative side
chains at these positions were operative in fusion-positive HAs (Cross
et al., 2001; Daniels et al., 1985; Gething et al., 1986; Korte et al., 2001;
Lai and Tamm, 2007; Lin et al., 1997; Nobusawa et al., 1995; Qiao et al.,
1999; Steinhauer et al., 1995; Yewdell et al., 1993). As such, it is
unlikely that the side chains present in the WT fusion peptide at
these positions are obligately required for folding of the native HA,
or for fusion activity following the acid-induced conformational
changes. Therefore, any consequences of their deletion are likely to
result from either a decrease in the overall length of the fusion
peptide, the disruption of critical motifs or structural elements
within this domain, or the relative length or spacing of such
features.tructure is shown on the left. Residues that will constitute the HA1 subunit following
s that ultimately form the fusion peptide at the N-terminus of HA2 are shown in yellow.
he trimer surface and the cleavage site is indicated. The center panel shows that most of
eing the relocation of N-terminal HA2 “fusion peptide” residues from the bottom of the
mer following the acid-induced conformational changes required for membrane fusion.
ain are located at the same end. Dashed lines indicate that the structure is unknown for
ructure. The antigenic sites A, B, and E are indicated for HA0 in the left panel, but these
re shown in the center panel. The region bound by low pH HA-speciﬁc antibody IIF4 is
fusion peptide region of cleaved neutral pH HA. The structural locations of HA2 residues
17 and HA2 residues 109 and 112 are also identiﬁed.
Table 1
Antibody reactivity of cell-surface HAs by ELISA (% of WT).
α-X31 HC100 HC159 HC31 HC68
WT 100 100 100 100 100
ΔL2 94 95 99 99 104
ΔG4 108 105 114 97 78
ΔI6 100 94 103 94 104
ΔF9 101 104 103 86 91
ΔN12 102 104 122 96 105
ΔE15 108 110 120 109 102
ΔD19 96 103 112 100 100
ΔF24 86 85 108 40 43
Values represent averages derived from at least three separate experiments.
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To analyze the effects of fusion peptide deletions on the structure
and function of mutant HAs, recombinant vaccinia viruses were
generated for their expression (Blasco and Moss, 1995). To assess HA
folding and cell surface transport, ELISA assays were employed to
determine antibody reactivity to recombinant vaccinia virus-infected
HA-expressing HeLa cell monolayers. The panel of antibodies utilized
included a rabbit polyclonal serum (α-X31) raised against puriﬁed
trimeric HA ectodomains (BHA), and several monoclonal antibodies
known to bind in conformation-speciﬁc fashion to the distinct
antigenic sites A, B, or E of the HA membrane distal head domains
(Daniels et al., 1983; Wiley and Skehel, 1987). The antibodies HC100
(site E), and HC159 (site A) bind to locations within the HA that
remain structurally intact after the low pH conformational change
occurs (Fig. 2). By contrast, the antibodies HC31 and HC68 bind to
regions within site B at the membrane distal trimer interface, which
are altered by de-trimerization of monomer head domains following
acidiﬁcation. The antibody reactivity to the mutant HA proteins is
summarized in Table 1 and is represented as the percent binding
compared to the WT HA as determined by OD450 ELISA readings. All
of the mutants displayed signiﬁcant reactivity with the rabbit poly-
clonal serum, indicating that they are capable of being transported to
the cell surface. The results with the HC100 and HC159 monoclonal
antibodies were consistent with this, as antibody reactivities for all
mutant HAs were comparable to WT HA. However, the results with
the neutral pH-speciﬁc antibodies HC31and HC68 demonstrated a
signiﬁcantly reduced reactivity for the ΔF24 mutant, suggesting an
altered conformation for this mutant HA.
Analysis of HA0 cleavage of cell-surface HAs
The HA0 precursor protein must be cleaved into the HA1 and HA2
subunits to activate membrane fusion potential. Using the recombi-
nant vaccinia virus system, the WT Aichi HA that we utilized in this
study is expressed on the surfaces of infected cells in its uncleaved
HA0 precursor form. Therefore, the capacity for cleavage activation of
HA0 following exposure of HA-expressing cell monolayers to
exogenous trypsin serves as an alternative assay for transport ofFig. 3. Cell surface expression of HAs as assayed by trypsin cleavage of HA0 into HA1 and HA
with or without trypsin and cell lysates were analyzed by western blot following SDS-PAGmutant HAs to the plasma membrane. Furthermore, western blot
analysis of the migration patterns of cleavage products can be used to
verify that mutant proteins are processed into HA1 and HA2 subunits
of characteristic size, which is a requirement for fusion function. Fig. 3
shows a western blot analysis of trypsin cleavage of WT and mutant
HAs expressed on the surface of recombinant vaccinia virus-infected
cells. The results demonstrate that, with the exception of theΔF24 HA,
all mutant proteins were transported to the surface of infected cells
and display HA1 and HA2 cleavage products that resemble WT HA.
These results, in conjunction with the ELISA data described above,
suggest that the ΔF24 HA is misfolded on the cell surface relative to
WT HA and the other mutants. We have observed similar results with
several mutant HAs in previous studies (Li et al., 2008; Thoennes et al.,
2008), and our interpretation is that such mutants are expressed on
the cell surface in a conformation that is distinct from that of WT HA,
and that some features of this conformation are similar to those of the
low pH HA structure. HA2 residue 24 is located in the membrane
distal portion of an antiparallel β-sheet structure. In a previous study
designed to examine the length of peptide segment linked to the
fusion peptide, many of the pairwise deletions N-terminal to HA2
residue 24 and located in the antiparallel β-sheet structure of HA0 and
neutral pH cleaved HA displayed folding and expression properties
similar to ΔF24 HA (Li et al., 2008).
Analysis of the pH of conformational change
Having veriﬁed that all mutant proteins except the ΔF24 HA
express in native form on the cell surface and are capable of cleavage
activation, we next examined the ability of the expressed HAs to
undergo the acid-induced conformational changes required for fusion
activity. First, we used an ELISA-based assay to assess the relative
reactivities of the mutant HAs with two conformation-speciﬁc
antibodies: HC3, which recognizes site A of both the neutral and
low-pH HA conformations, and HC68, which preferentially binds to
the neutral pH HA at site B (Fig. 2). Recombinant vaccinia virus-
infected HeLa cells that were expressing HA0 on the cell surface were
treated with trypsin to cleave HA0 into HA1 and HA2, washed with
PBS, and incubated with PBS/citrate buffers in increments ranging in
pH from 5.6 down to 4.5. Monolayers were then neutralized, ﬁxed,
and assessed for reactivity to HC68 and HC3 by ELISA. The relative
ratios of HC68 to HC3 reactivity as determined by ELISA OD450 were
plotted as a function of pH and are shown in Fig. 4. A reduction in
these ratios is indicative that the HA can undergo the acid-induced
conformational changes required for membrane fusion. The results
demonstrate that the Δ24F HA binds poorly to HC68 at all pH values
examined, conﬁrming that this mutant is expressed in an altered
conformation on the cell surface. Most other mutants exhibited a
decrease in HC68:HC3 reactivity over the range of pH reductions that
were tested, indicating that they are capable of undergoing the
characteristic conformational changes associated with membrane
fusion. The reactivity proﬁle for the ΔE15 and ΔD19 HA mutants are
not signiﬁcantly different from that of WT HA, indicating that they2. Recombinant vaccinia virus-infected HA-expressing cell monolayers were incubated
E under reducing conditions.
Fig. 4. Graphs of ELISA experiments to demonstrate HA conformational changes
resulting from incubation at reduced pH. Graphs plot the ratios of HC68/HC3 reactivity
as a function of pH. HC68 binds well with neutral pH HA, but poorly to the low pH
structure. HC3 binds equally well with both HA conformations.
Fig. 5. Graphs of ELISA experiments showing reactivity with the low pH-speciﬁc
monoclonal antibody IIF4 as a function of pH.
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displayed an elevated pH of conformational change relative toWT HA,
conﬁrming results that were obtained in a previous study (Steinhauer
et al., 1995). Similarly, the ΔG4 and ΔI6 also appear to undergo
structural rearrangements at elevated pH compared to WT. This
suggests that these mutations might alter interactions that occur in
native WT HA between fusion peptide residues and those located in
the trimer interior, resulting in a less stable neutral pH structure.
Previous reports demonstrate that a majority of fusion peptide
substitution mutants with changes within the ﬁrst 10 N-terminal
residues of HA2 display an elevated pH of conformational change
(Cross et al., 2001; Daniels et al., 1985; Gething et al., 1986; Lin et al.,
1997; Qiao et al., 1999; Steinhauer et al., 1995). This is likely due to the
fact that fusion peptide residues in this region make extensive contact
with ionizable residues such as HA1 H17, HA2 D109, and HA2 D112 in
this region of neutral pH HA following HA0 cleavage. The aspartic acid
side chains of HA2 residues 109 and 112 form multiple hydrogen
bondswith residues 1 through 5 of HA2, andHA1H17 forms hydrogen
bonds via a watermolecule with HA2 residues 6 and 10. Therefore, the
deletion of residues L2, G4, I6, or F9 could result in the disruption of
one or more of the interactions between fusion peptide residues andionizable residues in the neutral pH structure, thus destabilizing the
neutral pH structure.
The pH proﬁle observed for the ΔF9 HA was somewhat aberrant
compared to the others, and was not consistent with a loss of HC68
reactivity at reduced pH, even though this mutant appeared to be
expressed in the correct conformation on the surfaces of infected cells
and was efﬁciently cleaved into HA1 and HA2. In addition, the ΔI6 and
ΔN12 mutant HAs displayed a gradual loss of HC68 reactivity over a
broader range of pH than we generally observe forWT andmost other
mutant HAs. The disruption of interactions with HA1 H17 could offer a
possible explanation for this, as HA1 H17 has been implicated
previously for its potential role in the initial triggering of the acid-
induced conformational changes (Thoennes et al., 2008). A further
examination of the capacity for these mutants to undergo structural
rearrangements was carried out using an alternative conformation-
speciﬁc monoclonal antibody, IIF4. This anti-peptide antibody was
generated against residues 125-175 of the HA2 subunit and binds
preferentially to the low-pH form of the protein at the end of the
helical rod structure opposite to the fusion peptide (Vareckova et al.,
2002; Wharton et al., 1995). As shown in Fig. 5, an increase in IIF4
reactivity upon reduction in pH can be observed for ΔI6, ΔF9, and
ΔN12, as well as other HAs, indicating that structural rearrangements
have occurred.
Fig. 6.Western blot analysis for the determination of the pH of conformational change by trypsin susceptibility. HA expressing cells were treated with trypsin to cleave HA0, washed,
pH was adjusted to pH 4.6, and monolayers were again treated with trypsin. Lysates were then analyzed by western blot following SDS-PAGE under reducing conditions. The
disappearance of HA1 bands indicates that the HA conformational changes have been triggered.
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mutant HAs to undergo acid-induced conformational changes, we
carried out trypsin digestion experiments on cleaved HAs at neutral
pH, or following incubation at pH 5.0. Once the HA0 precursor has
been cleaved into HA1 and HA2, the WT protein is resistant to further
protease digestion at neutral pH. However, upon acidiﬁcation, the
structural changes render the molecule susceptible to digestion by a
variety of proteases, including trypsin (Skehel et al., 1982). For this
experiment, HA-expressing cell monolayers were initially treated
with trypsin to cleave HA0 into HA1 and HA2, as described for Fig. 3.
The monolayers were then washed, and either subjected to an
additional round of trypsin digestion at pH 7.2, or incubated at pH 4.6
prior to further trypsin treatment. Cell lysates were prepared and
analyzed by SDS-PAGE under reducing conditions. Fig. 6 shows that
the HA1 subunit of all mutants was digested by trypsin if the cleaved
HA had been exposed to acidic pH, demonstrating that the mutants
had gone through the characteristic conformational changes required
for fusion activity. For the neutral pH samples, the results of HA1
digestion for ΔF24 HA conﬁrm our interpretation that this HA isFig. 7. Polykaryon formation by HA-expressingexpressed in an altered conformation. However, the results with the
ΔF9 HA indicate that neutral pH HA1 was partially degraded by the
second trypsin digestion, as an additional band above HA2 was
observed, which is not present in the other samples. This product is
not observed during initial trypsin cleavage of HA0 into HA1 and HA2
at neutral pH (Fig. 3). This suggests that the ΔF9 HA may be unstable
relative to WT and most other mutant HAs, and this could explain the
aberrant results for HC68:HC3 antibody reactivities observed for the
experiments shown in Fig. 4. The conformational changes required for
fusion occur within seconds for WT Aichi HA, and the digestion of ΔF9
HA1 was still incomplete after two rounds of trypsin treatment over
several minutes. Therefore, it is quite possible that cell surface
expressed ΔF9 HA, or at least a signiﬁcant percentage of it, would be
capable of going through the structural rearrangements required for
fusion despite inherent instability. Cumulatively, the data suggest that
all deletion mutants other than ΔF24, and possibly ΔF9 HA, are
expressed and folded properly, and are capable of undergoing the
acid-induced structural rearrangements requisite for membrane
fusion.BHK cells following incubation at pH 4.8.
327W.A. Langley et al. / Virology 394 (2009) 321–330Analysis of membrane fusion by polykaryon formation and dye
transfer assays
The ability of the mutant proteins to mediate fusion was assessed
using an assay for polykaryon formation by recombinant vaccinia
virus-infected HA-expressing BHK21 cell monolayers. HA-expressing
cells were treated with trypsin to cleave HA0, the pH was adjusted by
incubation in PBS/citrate buffer, monolayers were then incubated in
complete medium at neutral pH, and monolayers were monitored for
polykaryon formation by light microscopy. Over multiple indepen-
dent experiments, no signiﬁcant polykaryon formation was detected
for any of the mutant HAs, even when tested in pH increments down
to 4.2. Fig. 7 shows representative ﬁelds of cells for one such assay
carried out at pH 4.8, which provides evidence that all mutants were
inhibited for membrane fusion activity.
To conﬁrm these results, a dye transfer assay was also performed
using the fusion peptide deletion mutants. For this assay, human
erythrocytes were labeled with two dyes, the lipophilic probe R18 and
the soluble dye calcein (Ellens et al., 1990; Morris et al., 1989). These
loaded erythrocytes were allowed to adhere to HA-expressing cell
monolayers, washed, and the pH of the monolayers were adjusted.
The dyes are transferred from the smaller erythrocytes to the largerFig. 8. Dye transfer assay for hemifusion and full fusion activity of HA mutants. Human eryth
to acidic pH to monitor HA mediated transfer of the lipid-soluble red dye R18 (lipid mixingHA-expressing HeLa cells if the HA is capable of mediating fusion. The
transfer of R18 is indicative of lipid mixing, and the transfer of calcein
demonstrates content mixing and therefore, biologically relevant
fusion activity. The transfer of R18, but not calcein is indicative of a
“hemifusion” phenotype, in which the lipid mixing stage of mem-
brane fusion does not proceed to full fusion with content mixing
(Kemble et al., 1994). The dye transfer assays were carried out
multiple times with the deletion mutants, and results for one such
experiment are shown in Fig. 8. None of the mutants were found
capable of mediating WT levels of membrane fusion using this assay.
No evidence for calcein transfer and content mixing was observed for
any mutant at all pH examined. However, for the Δ15 and Δ19
mutants, R18 transfer was detectable at levels above background in
some examples, suggesting that these mutants might be capable of
hemifusion activity, as has been observed for particular HAmutants in
previous studies (Cross et al., 2001; Kemble et al., 1994; Qiao et al.,
1999). Dye transfer experiments were repeated in the presence of
chlorpromazine (CPZ) in attempts to induce the transition from a
hemifusion to full fusion state (Melikyan et al., 1997); however, these
did not allow us to further deﬁne the mutant phenotypes. Concentra-
tions of CPZ ranging from 0.1 mM to 0.5 mM were tested, and at the
lower concentrations no changes in fusion properties were detected,rocytes loaded with R18 and calcein were adsorbed to HA-expressing cells and exposed
) or the water-soluble green dye calcein (content mixing).
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cytopathology of the HA-expressing cells (data not shown).
One of the most well characterized of the “hemifusion” HA
mutants is the fusion peptide substitution mutant G1S at the HA2 N-
terminus. This serine mutant was found to display hemifusion activity
by White and colleagues (Qiao et al., 1999) and in our laboratory
(Cross et al., 2001), and the biophysical and structural properties have
also been analyzed for G1S fusion peptide analogs (Li et al., 2003,
2005). Despite the well-documented hemifusion phenotype, we were
able to rescue the HA2 G1S mutant as an infectious virus (Cross et al.,
2001). However, this mutant was severely attenuated for replication,
and it rapidly reverted to WT despite the requirement for two
nucleotide substitutions to do so. This suggests that, while such
mutants provide useful tools for dissecting the mechanistic stages of
fusion at the biophysical level, they are likely to be irrelevant in any
natural environment.
Deletion mutants and models for fusion peptide structure
Overall, our studies suggest that the length of the fusion peptide
domain of inﬂuenza HA can inﬂuence the functional properties of
the molecule at different levels, but appears to be most critical for
the latter stages of fusion when this domain interacts with target
membranes. All mutants except the ΔF24 HA were expressed in
native conformation on the cell surface, can be cleaved into HA1 and
HA2, and could be triggered by acidiﬁcation to undergo the structural
changes required for membrane fusion. Therefore, the most profound
effects of the deletions are likely to involve the structure that these
domains adopt in association with target membranes. The structure
of the fusion peptide domain associated with membranes in the
context of full length HA is unknown. The structure of the HA
transmembrane anchor domain near the C-terminus of the molecule
is also unknown, and there is evidence that this domain may also
have a role in fusion (Armstrong et al., 2000; Chang et al., 2008;
Melikyan et al., 2000).
Hydrophobic photolabeling analyses have indicated that the 22 N-
terminal residues of HA2 interact with target membranes during
fusion, and the periodicity of labeling suggests that this segment
adopts an amphipathic α-helical structure (Durrer et al., 1996; Harter
et al., 1989). Circular dichroism and FTIR spectroscopy studies with
membrane-bound fusion peptide analogs indicated that they may
contain from 40% to 60% α-helical structure, with some studies also
suggesting the presence of β-structure (Gray et al., 1996; Han et al.,
1999; Lear and DeGrado, 1987; Murata et al., 1987; Rafalski et al.,
1991; Wharton et al., 1988). In some of these studies, a loose
correlation between helical content and fusogenicity was observed
(Burger et al., 1991; Lear and DeGrado, 1987; Wharton et al., 1988).
The oligomeric state adopted by fusion peptide domains in
association with target membranes remains to be determined, and
models involving monomeric peptides, trimeric peptides, and fusion
peptides complexed with HA transmembrane domains have been
proposed. Experiments using spin-labeling electron paramagnetic
resonance (EPR) techniques with cysteine mutants of the fusion
peptide region suggest that they associate with membranes in
monomeric form (Macosko et al., 1997). Monomeric fusion peptide
structures have also been proposed by Tamm and colleagues based on
workwith synthetic fusion peptide analogs containing a seven residue
solubilization domain (GCGKKKK) attached to the C-terminal end of
the ﬁrst 20 residues of HA2 (Han et al., 2001; Han and Tamm, 2000;
Lai et al., 2006; Lai and Tamm, 2007; Li et al., 2005). These synthetic
peptides have been shown to possess pH-dependent membrane
fusion activity, and their NMR structures in DPC micelles showed that
the WT peptide adopted an inverted V-shaped structure at both
neutral pH and pH 5.0, with the apex of the V located at the aqueous
interface (Han et al., 2001). In the neutral pH structure, an N-terminal
helix comprised of residues L2 to F9 is followed by a turn, which isstabilized by hydrogen bonds formed by residues G8 and F9 with
residues E11 and N12. In the C-terminal portion of the peptide,
residues W14-G20 form an extended structure with a bend between
residues G16 and M17. By comparison, in the pH 5 structure, residue
I10 extends the N-terminal helix and the turn region C-terminal to
this helix contains a slightly more acute bend. This kink region may be
stabilized by hydrophobic interactions between F9 and W14.
Additionally, the C-terminal half of the fusion segment folds into a
short 310 helix, and residues E15 and D19 are reoriented such that
apolar residues become aligned at the bottom face of the kinked
peptide. This generates a hydrophobic pocket, and allows the peptide
to assume a more closed and deeply inserted structure within the
membrane at acidic pH. NMR structural studies on mutant fusion
peptide analogues that are inhibited for fusion activity suggested a
structural signiﬁcance for the hinge region that lies in the middle of
the fusion peptide sequence (Hsu et al., 2002; Lai et al., 2006; Lai and
Tamm, 2007; Li et al., 2005). In the context of these structures, the
deletion mutants analyzed in our current study would clearly disrupt
structural features that may be critical for function, including the N-
terminal alpha-helical domain, the bend region, or the orientation or
presence of acidic residues at positions 15 and 19.
Other studies and models suggest that fusion peptides associate
with membranes in oligomeric form. Experiments with HA fusion
peptide analogs linked to coiled coil domains designed to promote
their trimerization, indicate that the trimeric peptides promote a
greater degree of liposomal content leakage and membrane mixing
than the monomeric form (Lau et al., 2004). A series of studies by
Chang and colleagues indicated that inﬂuenza HA fusion peptides can
loosely assemble in lipid bilayers (Chang et al., 2000, 2008; Cheng et
al., 2003), but further suggested that they form oligomeric complexes
with the HA transmembrane domains when both species are present.
These results are consistent with a role for the HA transmembrane
anchor domain in the fusion process, as suggested by mutagenesis
studies (Armstrong et al., 2000; Chang et al., 2008; Melikyan et al.,
2000).
Our results with recombinant inﬂuenza virus mutants within the
ﬁrst 10 residues of the fusion peptide (Cross et al., 2001) are
compatible with a model in which helical fusion peptides orient such
that the relatively polar glycine residues form a trimeric interface,
and the large hydrophobic side chains of residues 2, 6, and 10 reside
on the surface to interact with membrane lipids (Skehel et al., 2001).
In fact, many of the studies and models cited above suggest that the
N-terminal region of the fusion peptide domain is predominantly α-
helical. However, in the absence of structural information on fusion
peptide and transmembrane domains associated with membranes in
the context of full-length HA molecules, these models will continue
to be speculative. Regardless, our results with the deletion mutants
reported here suggest that structural elements along the length of
the fusion peptide, or the spacing or orientation of such elements
relative to one another, are critical for a functional association of
fusion peptide sequences with target membranes during the fusion
process.
Materials and methods
Mutagenesis and expression of HAs
The HA cDNA from the H3N2 subtype virus A/Aichi/2/68 was
mutated by site-directed mutagenesis using a QuikChange mutagen-
esis kit (Stratagene). The presence of the desired mutations and the
absence of extraneous mutations were conﬁrmed by nucleotide
sequencing of entire HA coding regions. The mutant cDNAs were
expressed as recombinant vaccinia viruses using the plaque-selection
system (Blasco and Moss, 1995). The generated viruses were
propagated on CV1 cells in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (FBS).
329W.A. Langley et al. / Virology 394 (2009) 321–330Cell surface expression trypsin cleavability and ELISA
HA cell surface expression was analyzed using a trypsin cleavage
assay with recombinant vaccinia-infected CV1 cells as described
previously (Steinhauer et al., 1995), except that blots were developed
using chemiluminescence rather than radiolabeled secondary anti-
body. Following electrophoresis, blots were incubated with anti-HA
rabbit polyclonal rabbit serum, washed, and incubated with a Protein
A-HRP conjugate (Sigma cat# P8651). Blots were developed with the
Enhanced Chemiluminescence Reagent (Amersham Pharmacia)
according to the manufacturer's instructions. Quantitative cell surface
expression by ELISA was carried out on recombinant vaccinia virus-
infected HA-expressing HeLa cells using a panel of monoclonal
antibodies that recognize distinct antigenic regions of wild-type HA
as described (Steinhauer et al., 1991).Conformational change analysis by ELISA and trypsin digestion
Analysis of conformation changes was performed on recombinant
vaccinia-infected HeLa cell monolayers by ELISA using monoclonal
antibodies HC3 and HC68 as described previously (Steinhauer et al.,
1991). HC3 recognizes both native and low pH HA, while HC68
recognizes only the native conformation. Trypsin susceptibility of
low-pH HAs were determined as described previously (Thoennes et
al., 2008).Polykaryon formation and dye transfer assays for membrane
fusion activity
The pH of membrane fusion was assayed by polykaryon formation
as described previously (Steinhauer et al., 1991, cited by in Scopus
(39)). For dye transfer assays, fresh heparinized human erythrocytes
(HRBCs) were co-labeled with the membrane probe octadecyl rhoda-
mine B chloride (R18) and the aqueous dye calcein-AM (Sigma) as
described previously (Ujike et al., 2005). Ten milliliters of freshly
prepared HRBCs (1% in Dulbecco's phosphate-buffered saline [DPBS])
was mixed with 10 μl of R18 (2 mM in ethanol) with vigorous
shaking. The mixture was incubated in the dark for 30 min at room
temperature, followed by the addition of 30 ml of 7.5% FBS- DMEM
for 20 min at room temperature to remove unbound R18. The R18-
labeled HRBCs were washed three times and resuspended in DPBS
(4% R18-labeled HRBCs). A 10-μl aliquot of 4 mM calcein-AM in
dimethyl sulfoxide was added to 1 ml of 4% R18-labeled HRBCs in the
dark and incubated at 37°C for 1 h, followed by the addition of 30 ml
of 7.5% FBS-DMEM for 20 min at room temperature, three washes
with DPBS to remove unbound calcein, and resuspension in DMEM
(0.02% HRBCs). To analyze hemifusion and fusion pore formation by
wildtype HA and HA mutants, an R18 and calcein transfer assay was
performed. Recombinant vaccinia virus-infected HeLa cells expres-
sing HA were pretreated with neuraminidase (NA) (30 mU/ml;
Sigma) at 37 °C for 60 min, washed once with DPBS, and treated with
TPCK-trypsin (5 μg/ml) at 37 °C for 5 min. Cells were washed with
soybean trypsin inhibitor (5 μg/ml), washed, and incubated with
R18- and calcein-labeled HRBCs at room temperature for 30 min for
hemadsorption. After unbound HRBCs were removed by three
washes, the cells were washed and incubated for 1 min at 37 °C in
low-pH buffer (10 mM HEPES, 20 mM sodium citrate [pH 5.0],
150 mM NaCl, 2 mM CaCl2, and 20 mM rafﬁnose to prevent colloidal-
osmotic swelling of the erythrocytes that could be induced by
HA-mediated leakage) (Melikyan et al., 1999). The medium was
replaced with DMEM supplemented with 7.5% FBS. After incubation
for 15 min at 37 °C, hemadsorption and the transfer of ﬂuorescence
were observed with a phase-contrast microscope and a ﬂuorescence
microscope, respectively.Acknowledgments
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